PeptiDream عائد حقوق الملكية 2024

ماذا تفعل PeptiDream؟

PeptiDream Inc is a Japanese biotech company specializing in novel therapeutics and drugs. The company was founded in 2006 by Professor Hiroaki Suga, who established the field of peptide synthesis at the University of Tokyo. Peptides are short chains of amino acids used in pharmaceutical development and diagnosis. PeptiDream uses a patented technology to generate billions of different peptides, which can then be systematically tested for functionality and applicability. The company also utilizes artificial intelligence and machine learning to specifically find compounds that can potentially treat cancer or neurodegenerative diseases. PeptiDream has four diverse business areas focusing on different applications. The first area is the identification of new drugs, where the company collaborates with several pharmaceutical and biotech firms to develop new compounds. The second area focuses on the development of peptide-based diagnostics. An example of this is the PeelAVERT technology, which identifies cancer-causing proteins through a "peeling process" of skin samples. This allows for personalized cancer treatment and improves success rates. The third area involves the development of agrochemicals. PeptiDream aims to replace chemical pesticides with biodegradable peptide-based compounds that have no negative impact on the environment. The fourth area aims to enhance quality of life through the use of peptides. The company focuses on compounds that can strengthen the immune system or slow down the aging process. PeptiDream has made several groundbreaking discoveries, including the PD-1 inhibitor technology for cancer treatment. This method uses peptides to activate the body's immune system and kill cancer cells. PD-1 inhibitors have shown promising results in clinical studies for lung cancer, kidney cancer, and other tumor types. PeptiDream has also developed a technology called "Peptide Discovery Platform System 2.0," which allows for the rapid generation and analysis of billions of diverse peptides. This method has been patented and enables PeptiDream to quickly focus on the development of new compounds. PeptiDream is a global leader in the development of peptide therapeutics and diagnostics. The company has earned an excellent reputation and collaborates closely with various research institutions, pharmaceutical companies, and biotech firms. PeptiDream also invests in training the next generation of scientists and strives to provide the industry and society with new compounds. PeptiDream ist eines der beliebtesten Unternehmen auf Eulerpool.com.